Publication — IRIC

A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens.

The search for tumor-specific antigens (TSAs) has considerably accelerated during the past decade due to the improvement of proteogenomic detection methods. This provides new opportunities for the development of novel antitumoral immunotherapies to mount an efficient T cell response against one or multiple types of tumors. While the identification of mutated antigens originating from coding exons has provided relatively few TSA candidates, the possibility of enlarging the repertoire of targetable TSAs by looking at antigens arising from non-canonical open reading frames opens up interesting avenues for cancer immunotherapy. In this review, we outline the potential sources of TSAs and the mechanisms responsible for their expression strictly in cancer cells. In line with the heterogeneity of cancer, we propose that discrete families of TSAs may be enriched in specific cancer types.

Publication date
December 3, 2020
Principal Investigators
Minati R, Perreault C, Thibault P
PubMed reference
Front Immunol 2020;11:583287
PubMed ID
École Normale Supérieure de Lyon, Université Claude Bernard Lyon I, Université de Lyon, Lyon, France.